Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by Tata Memorial Hospital.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Tata Memorial Hospital
Information provided by:
Tata Memorial Hospital
ClinicalTrials.gov Identifier:
NCT00652613
First received: March 27, 2008
Last updated: April 9, 2008
Last verified: April 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Head & Neck squamous cell carcinomas are the commonest cancers afflicting the developing countries. Traditionally surgery or radiotherapy alone in the early stages and surgery with postoperative radiotherapy in advanced stages have been the mainstay of treatment. Of late there has been a paradigm shift in the management of these cancers, particularly those of the oropharynx and laryngopharynx, where chemoradiation has been advocated as part of organ preservation protocol with good outcomes. Conventional radiotherapy involves the use of 2 or 3 field technique with or without compensators to encompass the volume at risk to radical doses of 66-70 Gy typically needed to sterilize gross disease. This strategy however is associated with considerable acute morbidity (mucositis, dysphagia, dermatitis) and debilitating late toxicity (xerostomia). Three dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) have the potential to improve the dose distribution, with increased doses to the target volumes and reduced doses to surrounding normal structures, thereby improving the therapeutic ratio.
| Condition | Intervention | Phase |
|---|---|---|
|
Squamous Cell Carcinoma of the Head and Neck |
Radiation: 3 Dimensional Radiation Therapy Radiation: Intensity Modulated Radiation Therapy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) vs Intensity Modulated Radiotherapy (IMRT) for Squamous Cell Carcinoma of the Head and Neck (HNSCC) |
Resource links provided by NLM:
Further study details as provided by Tata Memorial Hospital:
Primary Outcome Measures:
- Major salivary gland sparing by 3-D CRT vis-à-vis IMRT. Assess adequacy of target volume coverage [ Time Frame: 4 yrs ] [ Designated as safety issue: Yes ]
- Determine the pattern of local and loco-regional recurrence [ Time Frame: 4 yrs ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Disease Free Survival (DFS) and Overall Survival (OAS) [ Time Frame: 4 yrs ] [ Designated as safety issue: Yes ]
- Quality of life 3. Dose to OAR [ Time Frame: 4 yrs ] [ Designated as safety issue: Yes ]
- Assess the reduction in dose with IMRT to the normal larynx and normal pharyngeal constrictors in oropharyngeal cancers, uninvolved oral mucosa and auditory apparatus [ Time Frame: 4 yrs ] [ Designated as safety issue: Yes ]
| Enrollment: | 60 |
| Study Start Date: | August 2005 |
| Estimated Study Completion Date: | August 2009 |
| Estimated Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
3 dimensional conformal radiotherapy
|
Radiation: 3 Dimensional Radiation Therapy
Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
|
|
Experimental: 2
Intensity Modulated Radiation Therapy (IMRT)
|
Radiation: Intensity Modulated Radiation Therapy
IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Biopsy proven squamous cell carcinoma of the oropharynx or laryngopharynx.
- AJCC stage T1-3, NO-2b, MO patients with pre-treatment tumor measurements clinically as well as on CT/MRI scans.
- Surgery of the primary tumor limited to excisional or incisional biopsy.
- No form of neck dissection for nodal metastases.
- KPS > 60 (see appendix I).
- Age > 18 and < 65 years.
- No prior history of therapeutic irradiation.
- Patient willing and reliable for follow-up.
- Patient's nutritional & physical condition compatible with planned therapy.
Exclusion Criteria:
- Evidence of distant metastases.
- Previous therapeutic irradiation for head & neck cancer or any other invasive cancer other than squamous or basal cell carcinoma of the skin.
- History of prior malignancy.
- Prophylactic use of amifostine or pilocarpine.
- Active untreated infection like tuberculosis, which preclude the use of systemic chemotherapy or would interfere with completion of treatment.
- Any histopathology other than Squamous Carcinoma.
- Primary nasopharyngeal carcinoma.
- Age < 18 or > 65 years.
- Pregnancy or lactating women.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00652613
Locations
| India | |
| Tata Memorial Hospital | |
| Mumbai, Maharashtra, India, 400012 | |
Sponsors and Collaborators
Tata Memorial Hospital
Investigators
| Principal Investigator: | Sarbani Ghosh-Laskar, MD | Department of Radiation Oncology, Tata Memorial Centre |
| Study Director: | Ketayun Dinshaw, FRCR | Director, Tata Memorial Centre |
More Information
No publications provided
| Responsible Party: | Sarbani Ghosh-Laskar, Tata Memorial Centre |
| ClinicalTrials.gov Identifier: | NCT00652613 History of Changes |
| Other Study ID Numbers: | H&N_3DCRT_IMRT07 |
| Study First Received: | March 27, 2008 |
| Last Updated: | April 9, 2008 |
| Health Authority: | India: Institutional Review Board |
Keywords provided by Tata Memorial Hospital:
|
3DCRT IMRT HNSCC Quality of life |
Major salivary gland sparing Pattern of local and loco-regional recurrence Disease Free Survival (DFS) & Overall Survival (OAS) Dose reduction to normal structures with IMRT |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Squamous Cell Head and Neck Neoplasms Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Neoplasms by Site |
ClinicalTrials.gov processed this record on May 23, 2013